Pharmaceutical sciences

Terra Sigillata

Category archives for Pharmaceutical sciences

Just a quick post this morning as I am performing my professional responsibility to our nation’s health research agency. In yesterday’s issue of USA Today (which I only read on the iPhone app or when staying at a hotel that gives it to us free), Donna Leinwand wrote about a currently legal substitute for marijuana…

Thank you for visiting our introductory post on K2 Spice and welcome readers from Maia Szalavitz at the TIME Healthland blog. The comments to which she refers can be seen by scrolling to the end of the post. However, our blog has moved since this was posted in Feb 2010 and any further comments are…

After writing this post, I came across Alex’s obituary and guestbook on Legacy.com. By all accounts, Alex was a great kid – loved and admired by many – an accomplished hockey player and musician with a love for the mountains. This could have been you or I, or worse, one of our own children. Breaking…

A couple of colleagues turned me on the other morning to a press release by researchers at the University of Warwick who recently published in PNAS that their data apparently overturns the Meyer-Overton Rule regarding solubility of a compound in olive oil and its propensity for crossing biological membranes. I’m having trouble understanding exactly why…

The statin class of cholesterol-lowering agents is rich with history and lessons in the power of natural products, the potential of the prepared mind, and just how precarious the path of drug development can be. American Scientist, the official publication of the scientific research society Sigma Xi, hosts this issue an absolutely lovely article entitled,…

Jake Young, the MD/PhD student blogging at Pure Pedantry, has a great post this week on the detection of a novel formulation of the erythropoiesis stimulating agent (ESA) erythropoietin in Riccardo Riccó, the Italian cyclist who was thrown out of the Tour de France. Jake’s post is a superb primer on the use of this…

A paper in last month’s issue of Nature Reviews Drug Discovery reported that US drug approvals during 2007 were the lowest number since 1983. (17 new molecular entities and 2 biologicals; see this figure for 1996-2007 data.) The review cites increased regulatory action as a factor in this reduction, especially following high-profile post-marketing safety issues…

Last week we spent some time discussing the shortcomings of the generic vs. brand name drug debate, focusing on an example of non-bioequivalence between the antidepressant Wellbutrin XL and its generic competitors. Three days later, I then received an e-mail from one John Procter about a movement to get Washington to move forward on the…

The safety and effectiveness of medicines and other health products is dependent upon their proper use, particularly the proper route of administration. There are reasons why products are labeled as “for topical use only” or “do not swallow” – two recent warnings from the US FDA illustrate these issues. Allergic Reactions with Use/Misuse of Denture…

This issue was brought up by my fellow blogger, Joseph at Corpus Callosum, following an article in yesterday’s LA Times. For those not familiar with the concept or countries other than the US where laws may differ, generic drugs are those with the same active chemical as the originally-approved “brand name” drug. The original drug…